CpG island methylation in sporadic and neurofibromatis type 2-associated schwannomas

被引:3
|
作者
Gonzalez-Gomez, P
Bello, MJ
Alonso, ME
Lomas, J
Arjona, D
de Campos, JM
Vaquero, J
Isla, A
Lassaletta, L
Gutierrez, M
Sarasa, JL
Rey, JA
机构
[1] Univ Madrid, Hosp La Paz, Lab Oncogenet Mol, Dept Expt C, Madrid 28046, Spain
[2] Univ Madrid, Hosp La Paz, Dept Neurosurg, Madrid 28046, Spain
[3] Univ Madrid, Hosp La Paz, Dept Otolaryngol, Madrid 28046, Spain
[4] Univ Madrid, Hosp La Paz, Dept Pathol, Madrid 28046, Spain
[5] Hosp Rio Hortega, Dept Neurosurg, Valladolid, Spain
[6] Clin Puerta Hierro, Dept Neurosurg, Madrid, Spain
[7] Fdn Jimenez Diaz, Dept Pathol, E-28040 Madrid, Spain
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The purpose of this research was to examine the DNA methylation profile of schwannomas. Experimental Design: We examined the DNA methylation status of 12 tumor-related genes (NF2, RB1, p14(ARF), p16(INK4a), p73, TIMP-3, MGMT, DAPK, THBS1, caspase-8, TP53, and GSTP1) in 44 sporadic and/or NF2-associated schwannomas using methylation-specific PCR. Results: The most frequently methylated genes were THBS1 (36 %), p 73 (27 %), MGMT (20 %), NF2 and TIMP-3 (18%). The RB1/p16INK4a gene pair displayed aberrant methylayed alleles in 15% of cases, whereas methylation was relatively rare in the other genes (<5%). Methylation was tumor specific because it was absent in two nonneoplastic nerve sheath samples and two normeoplastic brain samples studied as controls. Conclusions: Our findings indicate that aberrant methylation seems to be a mechanism for NF2 gene inactivation, considered an early step in schwarmoma tumorigenesis, and as well, aberrant hypermethylation of other tumor-related genes might represent secondary events that also contribute to the development of these tumors.
引用
收藏
页码:5601 / 5606
页数:6
相关论文
共 50 条
  • [21] Analysis of CIC-associated CpG island methylation in oligoastrocytoma
    Sahm, F.
    Lass, U.
    Herold-Mende, C.
    von Deimling, A.
    Hartmann, C.
    Mueller, W.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2013, 39 (07) : 831 - 836
  • [22] CpG island methylation associated with premalignant stage of gastric carcinogenesis
    Kang, GH
    Shim, YH
    Ro, JY
    LABORATORY INVESTIGATION, 2001, 81 (01) : 87A - 87A
  • [23] Cochlear Implant Outcomes between Patients with Sporadic and Neurofibromatosis Type 2-Associated Vestibular Schwannoma
    Dornhoffer, James R.
    Haller, Travis
    Lohse, Christine M.
    Driscoll, Colin L. W.
    Neff, Brian A.
    Saoji, Aniket
    Link, Michael J.
    Carlson, Matthew L.
    OTOLOGY & NEUROTOLOGY, 2023, 44 (08) : 791 - 797
  • [24] Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas
    Blakeley, Jaishri O.
    Ye, Xiaobu
    Duda, Dan G.
    Halpin, Chris F.
    Bergner, Amanda L.
    Muzikansky, Alona
    Merker, Vanessa L.
    Gerstner, Elizabeth R.
    Fayad, Laura M.
    Ahlawat, Shivani
    Jacobs, Michael A.
    Jain, Rakesh K.
    Zalewski, Christopher
    Dombi, Eva
    Widemann, Brigitte C.
    Plotkin, Scott R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (14) : 1669 - U220
  • [25] CpG island methylation as an early event during adenoma progression in carcinogenesis of sporadic colorectal cancer
    Kim, HC
    Roh, SA
    Ga, IH
    Kim, JS
    Yu, CS
    Kim, JC
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 20 (12) : 1920 - 1926
  • [26] Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas
    Tamura, Ryota
    Morimoto, Yukina
    Sato, Mizuto
    Kuranari, Yuki
    Oishi, Yumiko
    Kosugi, Kenzo
    Yoshida, Kazunari
    Toda, Masahiro
    JOURNAL OF NEURO-ONCOLOGY, 2020, 146 (02) : 265 - 273
  • [27] Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas
    Ryota Tamura
    Yukina Morimoto
    Mizuto Sato
    Yuki Kuranari
    Yumiko Oishi
    Kenzo Kosugi
    Kazunari Yoshida
    Masahiro Toda
    Journal of Neuro-Oncology, 2020, 146 : 265 - 273
  • [28] CPG ISLAND DNA METHYLATION SITES ARE ASSOCIATED WITH MALIGNANT POTENTIAL IN MENINGIOMAS
    Barnholtz-Sloan, Jill S.
    Adams, Mark D.
    Cohen, Mark
    Devine, Karen
    Wolinsky, Yingli
    Bambakidis, Nicholas
    Selman, Warren
    Miller, Robert
    Sloan, Andrew E.
    NEURO-ONCOLOGY, 2010, 12 : 62 - 63
  • [29] Serotonin transporter mRNA levels are associated with the methylation of an upstream CpG island
    Philibert, Robert
    Madan, Anup
    Andersen, Allan
    Cadoret, Remi
    Packer, Hans
    Sandhu, Harinder
    AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2007, 144B (01) : 101 - 105
  • [30] Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype
    Toyota, M
    Ahuja, N
    Suzuki, H
    Itoh, F
    Ohe-Toyota, M
    Imai, K
    Baylin, SB
    Issa, JPJ
    CANCER RESEARCH, 1999, 59 (21) : 5438 - 5442